QUITE A QUARTER: Biotech giant Amgen surprised Wall Street with revenue of $4.48 billion, $400 million above expectations, and profit of $1.43 billion or $1.83 per share, 29 cents more than anticipated. Its stock jumped more than 5 percent.
PERFORMANCE KEYS: Most Amgen drugs had higher sales, and the company got a one-time $206 million gain from selling its share of an experimental lung cancer drug.
Recommended Stories
RESEARCH PROGRESS: New CEO Robert Bradway says Amgen will do late-stage patient tests on three experimental drugs, for high cholesterol, osteoporosis and a thyroid disorder in kidney disease patients.
